Loading…
Rebuild America’s Health Care Schools Act of 2025
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
Rebuild America’s Health Care Schools Act of 2025 This bill allows hospitals to receive reimbursement under Medicare for certain costs associated with training nursing and allied health students in settings other than the hospital itself. Currently, hospitals may receive reimbursement under Medicare for the reasonable costs associated with training nursing and allied health students if certain conditions are met; the criteria vary depending on whether the students are enrolled in an educational program that is operated by the hospital or another entity. If the students are part of a program that is operated by another entity, the training must occur at the hospital itself or in areas immediately surrounding the hospital in order to qualify for reimbursement (among other requirements). The bill allows hospitals to receive reimbursement for these costs if the training is conducted at an entity that is related to the hospital (i.e., common ownership or control). The bill requires the Centers for Medicare & Medicaid Services (CMS) to update regulations to reflect these changes. Additionally, the CMS may not recoup or reduce payments to hospitals with respect to costs that are allowed under the bill and must refund any such recoupments or reductions that occurred during the six-year period prior to the bill's enactment.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2026 · third_quarter · Pharmacy
Referred to the House Committee on Ways and Means.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372) and the SECURE 340B Act (H.R. 9599), issues related to 340B program nondiscrimination and contract pharmacy arrangements. [CN1.1] Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.
Client expense: $250,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
2026 · third_quarter · Health Issues
Medicare and Medicaid payment issues, alternative payment models, value-based healthcare/Medicare shared savings program; Health care workforce; Health care pricing transparency and tax-exempt organization policy; Site Neutral; 340B Program and Drug Pricing; MA prior authorization (S. 1816 / H.R. 3514); Telehealth and digital health and remote monitoring; Home health / Hospice; Rural health and Rural Hospital Support Act (S. 335); Graduate medical education; Artificial intelligence; RESULTS Act (H.R. 5269 / S. 2761); Equitable Community Access to Pharmacist Services (ECAPS) Act (H.R. 3164 / S. 2426); 340B PATIENTS Act (H.R. 4581 / S. 2372); CONNECT for Health Act (H.R. 4206 / S. 1261); H.R. 1708 / S. 1087 Rebuild America's Healthcare Schools Act of 2025; Medicare Physician Reimbursement/MACRA reform.
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS)
2026 · third_quarter · Health Issues
Telehealth Community Project Funding / Congressionally directed spending Post-acute care, home health, and hospice payment policies Tele-home health Medicare Payment Policy and fraud, waste, and abuse efforts Medicare Shared Savings Program and value based health care 340B / Drug pricing Site neutral policy Hospital at Home Cybersecurity Rural Health Artificial intelligence Digital health Food / Nutrition / SNAP / WIC Medicaid and H.R. 1 implementation Alternative payment models Hospital price transparency and tax-exempt hospital policies H-1B visas / Immigration Community Development Financial Institutions Housing Student Loans and Workforce Development Programs / WIOA Reauthorization MACRA / Medicare Physician Reimbursement The Affordable Care Act Clinical / biomedical research Nursing and Allied Health Education (H.R. 1708 / S. 1087) GME for physicians / Medical Education
Client expense: Not reported · Firm income: $50,000
2026 · third_quarter · Medicare/Medicaid
Potential payment and delivery innovation models; H.R. 1708/S. 1087, the Rebuild Americas Health Care Schools Act; Possible reconciliation legislation, site neutrality, policies pertaining to premium subsidies, and implementation of Medicaid policies in H.R. 1.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Medicare & Medicaid funding; State Directed Payment issues; S. 1087 and H.R. 1708, the Rebuild Americas Healthcare Schools Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Medicare and Medicaid payment issues, alternative payment models, value-based healthcare/Medicare shared savings program; Health care workforce; Health care pricing transparency; Site Neutral; 340B Program and Drug Pricing; MA prior authorization (S. 1816 / H.R. 3514); Telehealth and digital health; Home health / Hospice; Rural health and Rural Hospital Support Act (S. 335); Graduate medical education; Artificial intelligence; The Affordable Care Act; RESULTS Act (H.R. 5269 / S. 2761); Equitable Community Access to Pharmacist Services (ECAPS) Act (H.R. 3164 / S. 2426); 340B PATIENTS Act (H.R. 4581 / S. 2372); CONNECT for Health Act (H.R. 4206 / S. 1261); H.R. 1708 / S. 1087 Rebuild America's Healthcare Schools Act of 2025; Medicare Physician Reimbursement/MACRA.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Pharmacy
The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (H.R. 5526/S. 1954) and Expedited Access to Biosimilars Act (H.R. 9661), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372), issues related to 340B program nondiscrimination and contract pharmacy arrangements. Issues related to manufacturer attempts to undercut the 340B program, including conversion of the program to a rebate model (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation). The Stop Pills That Kill Act (H.R. 8005), PRESS Act (H.R. 7184), and Fight Illicit Pill Presses Act (H.R. 5880), issues related to halting the unlawful production and availability of fentanyl, fentanyl analogues, and fentanyl-related substances. The States Handling Access to Reciprocity for Employment (SHARE) Act of 2025 (H.R. 4122), issues related to the Federal Bureau of Investigation (FBI) providing criminal history records to state licensing agencies under interstate compacts, which would help pharmacists and other healthcare professionals to more easily work across state lines.
Client expense: $260,000 · Firm income: Not reported
2026 · second_quarter · Medicare/Medicaid
Potential payment and delivery innovation models; H.R. 1708/S. 1087, the Rebuild Americas Health Care Schools Act; Possible reconciliation legislation, site neutrality, policies pertaining to premium subsidies, and implementation of Medicaid policies in H.R. 1.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
Medicare & Medicaid funding; State Directed Payment issues; S. 1087 and H.R. 1708, the Rebuild Americas Healthcare Schools Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Telehealth Community Project Funding / Congressionally directed spending Post-acute and home health care payments Tele-home health Medicare Payment Policy and fraud, waste, and abuse efforts Medicare Shared Savings Program and value based health care 340B / Drug pricing Site neutral policy Hospital at Home Cybersecurity Rural Health Artificial intelligence Digital health Food / Nutrition / SNAP / WIC Medicaid Alternative payment models Hospital price transparency H-1B visas / Immigration Community Development Financial Institutions Housing Student Loans and Workforce Development Programs / WIOA Reauthorization MACRA / Medicare Physician Reimbursement The Affordable Care Act Clinical / biomedical research Nursing and Allied Health Education (H.R. 1708 / S. 1087) GME for physicians
Client expense: Not reported · Firm income: $50,000
2026 · second_quarter · Health Issues
Medicare and Medicaid payment issues, alternative payment models, value-based healthcare/Medicare shared savings program; Health care workforce; Health care pricing transparency; Site Neutral; 340B Program and Drug Pricing; MA prior authorization (S. 1816 / H.R. 3514); Telehealth and digital health; Home health / Hospice; Rural health and Rural Hospital Support Act (S. 335); Graduate medical education; Artificial intelligence; The Affordable Care Act; RESULTS Act (H.R. 5269 / S. 2761); Equitable Community Access to Pharmacist Services (ECAPS) Act (H.R. 3164 / S. 2426); 340B PATIENTS Act (H.R. 4581 / S. 2372); CONNECT for Health Act (H.R. 4206 / S. 1261); H.R. 1708 / S. 1087 Rebuild America's Healthcare Schools Act of 2025; Medicare Physician Reimbursement/MACRA.
Client expense: Not reported · Firm income: $80,000
2026 · second_quarter · Medicare/Medicaid
Discussions related to proposed Medicare and Medicaid budgets related to energy and commerce and ways of means draft proposals. Advocating in support of S.1087 and H.R.1708.
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Medicare/Medicaid
Discussions related to proposed Medicare and Medicaid budgets related to energy and commerce and ways of means draft proposals. Advocating in support of S.1087 and H.R.1708.
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Pharmacy
The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (S. 1954), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372), issues related to 340B program nondiscrimination and contract pharmacy arrangements. Issues related to manufacturer attempts to undercut the 340B program, including conversion of the program to a rebate model (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to patient access to antipsychotic medication in long-term care settings (generally, no specific legislation).
Client expense: $240,000 · Firm income: Not reported
2026 · first_quarter · Medicare/Medicaid
Potential payment and delivery innovation models; H.R. 1708/S. 1087, the Rebuild Americas Health Care Schools Act; Possible reconciliation legislation, site neutrality, policies pertaining to premium subsidies, and implementation of Medicaid policies in H.R. 1.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Medicare/Medicaid
Discussions related to proposed Medicare and Medicaid budgets related to energy and commerce and ways of means draft proposals. Advocating in support of S.1087 and H.R.1708.
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · fourth_quarter · Pharmacy
The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (S. 1954), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372), issues related to 340B program nondiscrimination and contract pharmacy arrangements. Issues related to manufacturer attempts to undercut the 340B program, including conversion of the program to a rebate model (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation).
Client expense: $250,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
2025 · fourth_quarter · Medicare/Medicaid
Potential payment and delivery innovation models; H.R. 1708/S. 1087, the Rebuild Americas Health Care Schools Act; Medicaid funding and budget reconciliation; H.R. 1/One Big Beautiful Bill; Implementation of Rural Health Transformation Fund.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Medicare/Medicaid
H.R. 1708/S. 1087, Rebuild Americas Health Care Schools Act H.R. 4093, Apples to Apples Comparison Act H.R. 5269/S. 2761, Reforming and Enhancing Sustainable Updates on Laboratory Testing Services Act (RESULTS) H.R. 5371, Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act H.R. 6010/S. 1105, No UPCODE Act
Client expense: $180,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · third_quarter · Medicare/Medicaid
Discussions related to proposed Medicare and Medicaid budgets related to energy and commerce and ways of means draft proposals. Advocating in support of S.1087 and H.R.1708.
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · third_quarter · Medicare/Medicaid
Potential payment and delivery innovation models; H.R. 1708/S. 1087, the Rebuild Americas Health Care Schools Act; Medicaid funding and budget reconciliation; H.R. 1/One Big Beautiful Bill; Implementation of Rural Health Transformation Fund.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Pharmacy
The Rebuild Americas Health Care Schools Act (H.R. 1708/S. 1087), issues related to pharmacy residency funding. Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The Biosimilar Red Tape Elimination Act (S. 1954), issues related to increased patient access to essential biosimilar medications. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). The 340B PATIENTS Act (H.R. 4581/S. 2372), issues related to 340B program nondiscrimination and contract pharmacy arrangements. Issues related to manufacturer attempts to undercut the 340B program, including conversion of the program to a rebate model (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation).
Client expense: $230,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
2025 · third_quarter · Health Issues
Increasing access to mental health and substance use treatment, including Methadone; Mental health & substance use disorder workforce; H.R. 1708/S. 1087, Rebuild America's Health Care Schools Act; Protect Medicaid from cuts; Federal funding for mental health and substance use programs, research and training; Medicare telehealth flexibilities; Extend federal flexibilities for teleprescribing of controlled substances; H.R. 2483, Reauthorization of Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act; H.R. 2509/S. 931, Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act; Transparency and streamline utilization management protocols including prior authorization and step therapy (H.R. 8702/S. 4532); Preventing and reducing suicide (H.R. 3505, H.R. 1987, S. 926); Extend Affordable Care Act (ACA) Enhanced Premium Tax Credits.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Medicare/Medicaid
Discussions related to proposed Medicare and Medicaid budgets related to energy and commerce and ways of means draft proposals. Advocating in support of S.1087 and H.R.1708.
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · second_quarter · Medicare/Medicaid
Potential payment and delivery innovation models; H.R. 1708/S. 1087, the Rebuild Americas Health Care Schools Act; Medicaid funding and budget reconciliation; H.R. 1/One Big Beautiful Bill.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
Increasing access to mental health and substance use treatment, including Methadone; Mental health & substance use disorder workforce; H.R. 3655, STAR Plus Scholarship Act; H.R. 1708/S. 1087, Rebuild America's Health Care Schools Act; Protect Medicaid from cuts; Federal funding for mental health and substance use programs, research and training; Medicare telehealth flexibilities; H.R. 2482, Reauthorization of Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act; H.R. 2509/S. 931, Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act; H.R. 2586, Reentry Act; H.R. 1510, Due Process Continuity of Care Act; Transparency and streamline utilization management protocols including prior authorization and step therapy (H.R. 8702/S. 4532); Preventing and reducing suicide (H.R. 3505, S. 1062, H.R. 1987, S. 926)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Medicare/Medicaid
Potential payment and delivery innovation models; H.R. 1708/S. 1087, the Rebuild Americas Health Care Schools Act; Medicaid funding and budget reconciliation.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Health Issues
Increasing access to mental health and substance use treatment, including Methadone; Mental health & substance use disorder workforce; H.R. 1708/S. 1087, Rebuild America's Health Care Schools Act; Protect Medicaid from cuts; Federal funding for mental health and substance use programs, research and training; Medicare telehealth flexibilities; H.R. 2482, Reauthorization of Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act; H.R. 2509/S. 931, Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act; H.R. 2586, Reentry Act; H.R. 1510, Due Process Continuity of Care Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Medicare/Medicaid
Discussions related to proposed Medicare and Medicaid budgets related to energy and commerce and ways of means draft proposals. Advocating in support of S.1087 and H.R.1708.
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Republican |
| NY |
| Daniel Meuser | Republican | PA |
| Don Bacon | Republican | NE |
| Donald G. Davis | Democratic | NC |
| Earl L. "Buddy" Carter | Republican | GA |
| Eleanor Holmes Norton | Democratic | DC |
| Emanuel Cleaver | Democratic | MO |
| Eugene Simon Vindman | Democratic | VA |
| Maxwell Frost | Democratic | FL |
| Michelle Fischbach | Republican | MN |
| Mike Kelly | Republican | PA |
| Randy Feenstra | Republican | IA |
| Robert J. Wittman | Republican | VA |
| Robert P. Bresnahan, Jr. | Republican | PA |
| Sarah McBride | Democratic | DE |
| Steve Cohen | Democratic | TN |
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
Government targets: HOUSE OF REPRESENTATIVES
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE